Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

NCT07116746 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout
Gouty Arthritis
Hyperuricemia
Gout Chronic
Refractory Gout
Uncontrolled Gout
Tophaceous Gout

Interventions

DRUG: AR882 75 mg
DRUG: XOI Low Dose
DRUG: XOI High Dose

Sponsor

Arthrosi Therapeutics